Shi-Wei Li, Yue Zeng, Sa-Nan Wu, Xin-Yue Ma, Chao Xu, Zong-Quan Li, Sui Fang, Xue-Qin Chen, Zhao-Bing Gao, Fang Bai
{"title":"Discovery of selective GluN1/GluN3A NMDA receptor inhibitors using integrated AI and physics-based approaches.","authors":"Shi-Wei Li, Yue Zeng, Sa-Nan Wu, Xin-Yue Ma, Chao Xu, Zong-Quan Li, Sui Fang, Xue-Qin Chen, Zhao-Bing Gao, Fang Bai","doi":"10.1038/s41401-025-01607-6","DOIUrl":null,"url":null,"abstract":"<p><p>N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels essential for synaptic transmission and plasticity in the central nervous system. GluN1/GluN3A, an unconventional NMDAR subtype functioning as an excitatory glycine receptor, has been implicated in mood regulation, with high expression in brain regions governing emotional and motivational states. However, therapeutic exploration has been significantly hindered by a lack of potent and selective modulators, limited structural data and the intrinsic complexity of ion channels. Here, we introduce a compound virtual screening pipeline that combines artificial intelligence and physical models, integrating two sequence-based deep learning prediction models (TEFDTA and ESMLigSite) with a molecular docking approach. This approach was employed to identify potential inhibitors against GluN1/GluN3A by screening a commercial database containing 18 million compounds. The strategy resulted in an impressive hit rate of 50% for discovering inhibitors, with the most promising compound exhibiting strong inhibitory activity (IC<sub>50</sub> = 1.26 ± 0.23 μM) and remarkable target specificity (>23-fold selectivity over the GluN1/GluN2A receptor). These findings highlight the effectiveness of AI-assisted strategies in addressing challenges related to unconventional ion channels and pave the way for new therapeutic exploration.</p>","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":" ","pages":""},"PeriodicalIF":6.9000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41401-025-01607-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels essential for synaptic transmission and plasticity in the central nervous system. GluN1/GluN3A, an unconventional NMDAR subtype functioning as an excitatory glycine receptor, has been implicated in mood regulation, with high expression in brain regions governing emotional and motivational states. However, therapeutic exploration has been significantly hindered by a lack of potent and selective modulators, limited structural data and the intrinsic complexity of ion channels. Here, we introduce a compound virtual screening pipeline that combines artificial intelligence and physical models, integrating two sequence-based deep learning prediction models (TEFDTA and ESMLigSite) with a molecular docking approach. This approach was employed to identify potential inhibitors against GluN1/GluN3A by screening a commercial database containing 18 million compounds. The strategy resulted in an impressive hit rate of 50% for discovering inhibitors, with the most promising compound exhibiting strong inhibitory activity (IC50 = 1.26 ± 0.23 μM) and remarkable target specificity (>23-fold selectivity over the GluN1/GluN2A receptor). These findings highlight the effectiveness of AI-assisted strategies in addressing challenges related to unconventional ion channels and pave the way for new therapeutic exploration.
n -甲基- d -天冬氨酸受体(NMDARs)是谷氨酸门控离子通道,对中枢神经系统突触传递和可塑性至关重要。GluN1/GluN3A是一种非常规的NMDAR亚型,具有兴奋性甘氨酸受体的功能,与情绪调节有关,在控制情绪和动机状态的大脑区域高表达。然而,由于缺乏有效和选择性的调节剂,有限的结构数据和离子通道的内在复杂性,治疗探索受到严重阻碍。在这里,我们介绍了一个结合人工智能和物理模型的复合虚拟筛选管道,将两个基于序列的深度学习预测模型(TEFDTA和ESMLigSite)与分子对接方法集成在一起。该方法通过筛选包含1800万种化合物的商业数据库来鉴定GluN1/GluN3A的潜在抑制剂。该策略在发现抑制剂方面取得了惊人的50%的命中率,其中最有希望的化合物具有很强的抑制活性(IC50 = 1.26±0.23 μM)和显著的靶标特异性(>对GluN1/GluN2A受体的选择性为23倍)。这些发现突出了人工智能辅助策略在解决非常规离子通道相关挑战方面的有效性,并为探索新的治疗方法铺平了道路。
期刊介绍:
APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.